Critical reviews in oncology/hematology最新文献_第2页

Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors 前列腺特异性膜抗原作为实体瘤血管导向治疗策略的靶点。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-17 DOI: 10.1016/j.critrevonc.2024.104556

Jisce R. Puik , Chung Le , Geert Kazemier , Daniela E. Oprea-Lager , Rutger-Jan Swijnenburg , Elisa Giovannetti , Arjan W. Griffioen , Elisabeth JM Huijbers

引用次数: 0

The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis 唐氏综合征患者中实体瘤和血液系统恶性肿瘤的发病率：系统回顾和荟萃分析。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-15 DOI: 10.1016/j.critrevonc.2024.104558

Nayara Rozalem Moretti , Ana Beatriz Nardelli da Silva , Letícia Vieira Guimarães , Ian de Paula Bezerra , João Arthur Cerqueira Taumaturgo , Natália Gabrielli Silva Alves , Francinny Alves Kelly , Francisco Cezar Aquino de Moraes

{"title":"The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis","authors":"Nayara Rozalem Moretti , Ana Beatriz Nardelli da Silva , Letícia Vieira Guimarães , Ian de Paula Bezerra , João Arthur Cerqueira Taumaturgo , Natália Gabrielli Silva Alves , Francinny Alves Kelly , Francisco Cezar Aquino de Moraes","doi":"10.1016/j.critrevonc.2024.104558","DOIUrl":"10.1016/j.critrevonc.2024.104558","url":null,"abstract":"<div><h3>Background</h3><div>Patients with Down syndrome (DS) have a unique genetic and clinical profile that may increase the risk of cancer.</div></div><div><h3>Methods</h3><div>A literature search on PubMed, Scopus, Web of Science, and the Cochrane databases was conducted, focusing on studies to investigate the prevalence of solid and hematologic tumors in DS.</div></div><div><h3>Results</h3><div>Fifteen studies were included, encompassing 62,121 individuals with Down syndrome (DS). The overall prevalence of cancer in DS was 2.02 % (95 % CI: 1.63–2.50 %). The analysis of hematological tumors revealed a prevalence of 1.18 % (95 % CI: 0.86 % - 1.62 %) for leukemia, 0.86 % (95 % CI: 0.73 % - 1.01 %) for acute lymphoblastic leukemia, and 0.51 % (95 % CI: 0.29 % - 0.90 %) for acute myeloid leukemia. Among solid tumors, testicular cancer had the highest prevalence, at 0.22 % (95 % CI: 0.12 % - 0.43 %).</div></div><div><h3>Conclusions</h3><div>Our results highlight the need for targeted screening strategies, prevention strategies and treatment protocols among those with Down syndrome.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104558"},"PeriodicalIF":5.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment 皮肤 T 细胞淋巴瘤的皮肤屏障功能障碍：从屏障损伤的致病机制到治疗。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-15 DOI: 10.1016/j.critrevonc.2024.104559

Pengfei Wen , Xiaoxue Zhuo , Lin Wang

引用次数: 0

A systematic literature review on clonal evolution events preceding relapse in multiple myeloma 关于多发性骨髓瘤复发前克隆进化事件的系统性文献综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-15 DOI: 10.1016/j.critrevonc.2024.104560

Maja Zimmer Jakobsen , Rasmus Froberg Brøndum , Henrik Gregersen , Hanne Due , Karen Dybkær

{"title":"A systematic literature review on clonal evolution events preceding relapse in multiple myeloma","authors":"Maja Zimmer Jakobsen , Rasmus Froberg Brøndum , Henrik Gregersen , Hanne Due , Karen Dybkær","doi":"10.1016/j.critrevonc.2024.104560","DOIUrl":"10.1016/j.critrevonc.2024.104560","url":null,"abstract":"<div><div>Despite considerable treatment advances<strong>,</strong> multiple myeloma (MM) remains an incurable hematological cancer due to treatment resistance. A systematic literature search was conducted to identify determinants for clonal evolution driving relapse and drug resistance in MM. A total of 631 non-duplicate publications were screened of which 28 articles were included for data extraction. Genetic alterations, mutational signatures, evolutionary trajectories, and non-genetic determinants were identified as key topics to characterize clonal evolution in relapsed MM. A variety of factors led to clonal diversification and increased tumor mutation burden, such as MAPK-Ras mutations and incremental changes related to chromosomal bands 1 and 17, while mutational signature analyses revealed that APOBEC activity and melphalan treatment leave a distinct impact on the clonal composition in MM genomes. To capture and dissect tumor heterogeneity, our review suggests combining methods or using technical approaches with high resolution to assess the impact of clonal evolution.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104560"},"PeriodicalIF":5.5,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spectrum and genotyping strategies of “dark” genetic matter in germline susceptibility genes of tumor syndromes 肿瘤综合征种系易感基因中 "暗 "遗传物质的谱系和基因分型策略。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-10 DOI: 10.1016/j.critrevonc.2024.104549

Anikó Bozsik , Henriett Butz , Vince Kornél Grolmusz , Tímea Pócza , Attila Patócs , János Papp

{"title":"Spectrum and genotyping strategies of “dark” genetic matter in germline susceptibility genes of tumor syndromes","authors":"Anikó Bozsik , Henriett Butz , Vince Kornél Grolmusz , Tímea Pócza , Attila Patócs , János Papp","doi":"10.1016/j.critrevonc.2024.104549","DOIUrl":"10.1016/j.critrevonc.2024.104549","url":null,"abstract":"<div><h3>Purpose</h3><div>Despite the widespread use of high-throughput genotyping strategies, certain mutation types remain understudied. We provide an overview of these often overlooked mutation types, with representative examples from common hereditary cancer syndromes.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive review of the literature and locus-specific variant databases to summarize the germline pathogenic variants discovered through non-routine genotyping methods. We evaluated appropriate detection and analysis methods tailored for these specific genetic aberrations. Additionally, we performed <em>in silico</em> splice predictions on deep intronic variants registered in the ClinVar database.</div></div><div><h3>Results</h3><div>Our study suggests that, aside from founder mutations, most cases are sporadic. However, we anticipate a relatively high likelihood of splice effects for deep intronic variants. The findings underscore the significant clinical utility of genome sequencing techniques and the importance of applying relevant analysis methods.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104549"},"PeriodicalIF":5.5,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 晚期非小细胞肺癌中的 KRAS 突变：从生物学到新型治疗策略。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-09 DOI: 10.1016/j.critrevonc.2024.104554

Luigi Liguori , Fabio Salomone , Angela Viggiano , Francesco Sabbatino , Stefano Pepe , Luigi Formisano , Roberto Bianco , Alberto Servetto

{"title":"KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies","authors":"Luigi Liguori , Fabio Salomone , Angela Viggiano , Francesco Sabbatino , Stefano Pepe , Luigi Formisano , Roberto Bianco , Alberto Servetto","doi":"10.1016/j.critrevonc.2024.104554","DOIUrl":"10.1016/j.critrevonc.2024.104554","url":null,"abstract":"<div><div>Kristen rat sarcoma viral oncogene homolog (<em>KRAS</em>) mutations play a major role in the carcinogenesis of many types of solid tumors including non-small cell lung cancer (NSCLC). Among <em>KRAS</em> mutations, p.G12C single-nucleotide variant (<em>KRAS</em><sup><em>G12C</em></sup>) is the most frequently reported in NSCLC patients, with a prevalence of about 12–13 %. For many decades, <em>KRAS</em> mutations including <em>KRAS</em><sup><em>G12C</em></sup> were considered “undruggable” because of the lack of effective and well-tolerated selective therapies. Noteworthy, CodeBreaK100 and KRYSTAL-1 clinical trials have recently demonstrated that sotorasib and adagrasib, two novel selective KRAS<sup>G12C</sup> inhibitors, have clinical activity with acceptable adverse-event profile for the treatment of advanced NSCLC patients with <em>KRAS</em><sup><em>G12C</em></sup> mutation. On the other hand, no selective therapies are approved for the treatment of advanced NSCLC patients with non-G12C <em>KRAS</em> mutations. As a result, these patients receive the same treatments as those without <em>KRAS</em> mutations. In this paper, we describe the role of <em>KRAS</em> mutations in NSCLC focusing on the clinical and molecular characteristics which potentially identify specific subtypes of NSCLC patients based on different <em>KRAS</em> mutations. We also provide an overview of the main clinical trials testing novel selective KRAS<sup>G12C</sup> inhibitors as well as novel potential therapeutic strategies for NSCLC patients with non-G12C <em>KRAS</em> mutations.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104554"},"PeriodicalIF":5.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expedited pathway insights: Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA 快速通道透视：揭开美国食品药物管理局（USFDA）和欧洲药品管理局（EMA）批准和撤销肿瘤和非肿瘤药物的神秘面纱。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-08 DOI: 10.1016/j.critrevonc.2024.104539

Purva Dayanand Chaugule , Priya Changdev Varpe , Ankita Arun Tandulje , Rajeev Singh Raghuvanshi , Saurabh Srivastava

{"title":"Expedited pathway insights: Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA","authors":"Purva Dayanand Chaugule , Priya Changdev Varpe , Ankita Arun Tandulje , Rajeev Singh Raghuvanshi , Saurabh Srivastava","doi":"10.1016/j.critrevonc.2024.104539","DOIUrl":"10.1016/j.critrevonc.2024.104539","url":null,"abstract":"<div><h3>Background</h3><div>Prior to entering the market, health authorities conduct a rigorous evaluation of compiled information for drugs delaying its entry. To address this void expedited pathways are introduced.</div></div><div><h3>Methods</h3><div>In this study, both oncology and non-oncology drugs approved through various expedited pathways from the US and Europe have been scrutinized using the USFDA’s Novel Drug approvals from 2020 to 2023 and EMA’s Human Medicine Highlights 2020 to 2023. Withdrawals if any along with factors causing withdrawal have also been studied.</div></div><div><h3>Results</h3><div>Among all the pathways accelerated approval has high oncological drug approvals and also high withdrawal for drugs approved based on surrogate endpoints. From the study conducted it was observed that intensive evaluation has to be performed both pre and post-approval for drugs approved based on surrogate endpoints as well as on the conduct of their confirmatory trials.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104539"},"PeriodicalIF":5.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of amino acid PET in radiotherapy target volume delineation for adult-type diffuse gliomas: A review of the literature 氨基酸 PET 在成人型弥漫性胶质瘤放疗靶区划分中的作用：文献综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-08 DOI: 10.1016/j.critrevonc.2024.104552

Patrick J. Horsley , Dale L. Bailey , Geoffrey Schembri , Edward Hsiao , James Drummond , Michael F. Back

{"title":"The role of amino acid PET in radiotherapy target volume delineation for adult-type diffuse gliomas: A review of the literature","authors":"Patrick J. Horsley , Dale L. Bailey , Geoffrey Schembri , Edward Hsiao , James Drummond , Michael F. Back","doi":"10.1016/j.critrevonc.2024.104552","DOIUrl":"10.1016/j.critrevonc.2024.104552","url":null,"abstract":"<div><h3>Purpose</h3><div>To summarise existing literature examining amino acid positron emission tomography (AA-PET) for radiotherapy target volume delineation in patients with gliomas.</div></div><div><h3>Methods</h3><div>Systematic search of MEDLINE and EMBASE databases.</div></div><div><h3>Results</h3><div>Twenty studies met inclusion criteria. Studies comparing MRI- and AA-PET- derived target volumes consistently found these to be complementary. Across studies, AA-PET was a strong predictor of the site of subsequent relapse. In studies examining AA-PET-guided radiotherapy at standard doses, including one study using reduced margins, survival outcomes were similar to historical cohorts whose volumes were generated using MRI alone. Four prospective single-arm trials examining AA-PET-guided dose-escalated radiotherapy reported mixed results. The two trials that used both a higher biologically-effective dose and boost-volumes defined using both MRI and AA-PET reported promising outcomes.</div></div><div><h3>Conclusion</h3><div>AA-PET is a promising complementary tool to MRI for radiotherapy target volume delineation, with potential benefits requiring further validation including margin reduction and facilitation of dose-escalation.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104552"},"PeriodicalIF":5.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nature killer cell for solid tumors: Current obstacles and prospective remedies in NK cell therapy and beyond 治疗实体瘤的自然杀伤细胞：NK 细胞疗法及其他疗法目前面临的障碍和未来的补救措施。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-06 DOI: 10.1016/j.critrevonc.2024.104553

Jia-Hao Tao , Jun Zhang , Hua-Shun Li , Yong Zhou , Cha-Xiang Guan

引用次数: 0

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review BCMA CAR-T诱导浆细胞性淋巴瘤同步转化为慢性淋巴细胞白血病的患者获得完全和持久缓解：病例报告和文献综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-05 DOI: 10.1016/j.critrevonc.2024.104551

Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang

{"title":"BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review","authors":"Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang","doi":"10.1016/j.critrevonc.2024.104551","DOIUrl":"10.1016/j.critrevonc.2024.104551","url":null,"abstract":"<div><div>Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton’s tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient’s CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104551"},"PeriodicalIF":5.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0